Yudao Shen

Yudao Shen

Icahn School of Medicine at Mount Sinai

H-index: 20

North America-United States

About Yudao Shen

Yudao Shen, With an exceptional h-index of 20 and a recent h-index of 20 (since 2020), a distinguished researcher at Icahn School of Medicine at Mount Sinai, specializes in the field of Medicinal chemistry and Organic chemistry.

His recent articles reflect a diverse array of research interests and contributions to the field:

Sox11 inhibitors for treating mantle cell lymphoma

Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells

PRMT inhibition induces a viral mimicry response in triple-negative breast cancer

Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of zeste homolog 2

Abstract LB195: AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B

Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic

Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras

Yudao Shen Information

University

Position

/SIOC

Citations(all)

1570

Citations(since 2020)

1455

Cited By

393

hIndex(all)

20

hIndex(since 2020)

20

i10Index(all)

25

i10Index(since 2020)

24

Email

University Profile Page

Google Scholar

Yudao Shen Skills & Research Interests

Medicinal chemistry and Organic chemistry

Top articles of Yudao Shen

Sox11 inhibitors for treating mantle cell lymphoma

2023/8/3

Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader

Oncogene

2023/3/24

Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells

Journal of medicinal chemistry

2022/10/5

Targeting triple-negative breast cancer by a novel proteolysis targeting chimera degrader of enhancer of zeste homolog 2

ACS Pharmacology & Translational Science

2022/6/24

Abstract LB195: AKT degradation selectively inhibits the growth of PI3K/PTEN pathway mutant cancers with wild type KRAS and BRAF by destabilizing Aurora kinase B

Cancer Research

2022/6/15

Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic

Oncogene

2022/6/10

Exploring degradation of mutant and wild-type epidermal growth factor receptors induced by proteolysis-targeting chimeras

Journal of medicinal chemistry

2022/6/8

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

Nature cell biology

2022/3

Discovery of potent, selective, and in vivo efficacious AKT kinase protein degraders via structure–activity relationship studies

Journal of medicinal chemistry

2022/2/4

AKT degradation selectively inhibits the growth of PI3K/PTEN pathway–mutant cancers with wild-type KRAS and BRAF by destabilizing aurora kinase B

Cancer discovery

2021/12/1

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models

Science translational medicine

2021/9/29

Harnessing the E3 ligase KEAP1 for targeted protein degradation

Journal of the American Chemical Society

2021/9/14

Pharmacologic modulation of RNA splicing enhances anti-tumor immunity

Cell

2021/7/22

Cancer selective target degradation by folate-caged PROTACs

Journal of the American Chemical Society

2021/5/10

A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6

Journal of medicinal chemistry

2021/2/16

Design, synthesis, and evaluation of potent, selective, and bioavailable AKT kinase degraders

Journal of medicinal chemistry

2021/12/2

Discovery of First-in-class Protein Arginine Methyltransferase 5 (PRMT5) Degraders

Journal of medicinal chemistry

2020/8/11

Discovery of a First-in-class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor

Journal of medicinal chemistry

2020/5/5

See List of Professors in Yudao Shen University(Icahn School of Medicine at Mount Sinai)